IRMDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
IRADIMED CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$87.65−0.62 (-0.70%)
Close on Oct 19, 2026
- Market cap
- $1.13B
- P/E (TTM)
- 49.0
- Dividend yield
- –
Share price
+$14.22 (+19.37%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
IRADIMED CORP grew revenue 11.2% to $86.34M over the twelve months to Jun 30, 2026. Operating income rose 15.7% to $27.56M, moving the operating margin from 30.7% to 31.9%. Free cash flow was $25.12M, up 76.8% from a year earlier.
Revenue
$86.34M
+11.2% vs. a year earlier
Operating income
$27.56M
+15.7% vs. a year earlier
Free cash flow
$25.12M
+76.8% vs. a year earlier
EPS, diluted
$1.79
+10.5% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.13B
- P/E ratio
- 49.0
- Price to sales
- 13.07
- Price to book
- 11.09
- Dividend yield
- –
- Free cash flow yield
- 2.23%
Fundamentals
- Revenue
- $86.34M
- Net income
- $23.05M
- EPS, diluted
- $1.79
- Free cash flow
- $25.12M
- Book value per share
- $7.90
- Diluted shares
- 13M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$86.34M+11.2% YoY
Gross profit
$65.50M+9.6% YoY
Operating income
$27.56M+15.7% YoY
Net income
$23.05M+11.6% YoY
EPS, diluted
$1.79+10.5% YoY
Free cash flow
$25.12M+76.8% YoY
Reported periodTrailing twelve months